Browse All

Current Filters

CLEAR FILTER x

TITLE

Real-world Effectiveness, Tolerability, and Safety of Ofatumumab at 12-month Follow-up

Author:Hersh, Carrie   Amin, Moein   Harvey, Tucker   Moss, Brandon   Tai, Ming-Hui   Gadkari, Abhijit   Brown, Brandon   Conway, Devon   

Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

Topic:Multiple Sclerosis  

Program Number:P9.014  

Author Institution:Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV  Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH  Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH  Novartis Pharmaceuticals Corporation, East Hanover, NJ  

Real-world Evidence of Adding Atogepant to OnabotulinumtoxinA for Control of Chronic Migraine: A Retrospective Chart Review

Author:Blumenfeld, Andrew   Mechtler, Laszlo   Cook, Lisa   Rhyne, Christopher   Jenkins, Brian   Hughes, Olivia   Dabruzzo, Brett   Adams, Aubrey   Diamond, Merle   

Session Name:P4: Headache in the Real World  

Topic:Headache  

Program Number:P4.001  

Author Institution:The Los Angeles Headache Center, Los Angeles, CA  Dent Neurologic Institute, Buffalo, NY  Norton Neuroscience Institute, Lousiville, KY  Neuroscience Group, Neenah, WI  ICON Plc, Blue Bell, PA  AbbVie Inc., Frederick, MD  AbbVie Inc., Irvine, CA  Diamond Headache Clinic, Chicago, IL  

Real-world Evidence of Efficacy, Use, and Discontinuation of Pharmacotherapies for the Treatment of Essential Tremor

Author:Gerbasi, Margaret   Tu, Lufei   Chertavian, Elizabeth   Nejati, Mina   LeWitt, Peter   

Session Name:P3: Movement Disorders: Essential Tremor and Other Tremor Disorders  

Topic:Movement Disorders  

Program Number:P3.006  

Author Institution:Sage Therapeutics, Inc., Cambridge, MA  Medicus Economics, LLC, Milton, MA  Biogen Inc., Belmont, MA  Wayne State University School of Medicine  Henry Ford Hospital, West Bloomfield, MI  

Real-world Evidence on Treatment Retention, Safety, and Tolerability of Edaravone in Canadian Patients with Amyotrophic Lateral Sclerosis

Author:Pham, Dung   St-Onge, Louise   Ng, Ryan   Neish, Calum S.   Yap, Belinda   Kainth, Pinay   Apple, Stephen   

Session Name:P5: Neuromuscular and Clinical Neurophysiology (EMG): Amyotrophic Lateral Sclerosis 1  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:P5.012  

Author Institution:Mitsubishi Tanabe Pharma Canada, Inc., Toronto, ON, Canada  IQVIA Solutions Canada, Inc., Mississauga, ON, Canada  Innomar Strategies, Oakville, ON, Canada  Mitsubishi Tanabe Pharma America, Inc., Jersey City, NJ  

Real-world Experience of Switching Treatments from Alglucosidase Alfa to Avalglucosidase Alfa for Patients Enrolled in the Pompe Registry

Author:Dimachkie, Mazen   Kishnani, Priya   Abbott, Mary-Alice   Toscano, Antonio   Foster, Meredith   Sparks, Susan   Schoser, Benedikt   

Session Name:P3: Neuromuscular and Clinical Neurophysiology (EMG): Genetic Muscle Diseases  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:P3.007  

Author Institution:University of Kansas Medical Center, Kansas City, KS  Duke University Medical Center, Durham, NC  Baystate Health, Springfield, MA  Reference Center for Rare Neuromuscular Disorders, University of Messina, Messina, Italy  Sanofi, Cambridge, MA  Friedrich-Baur-Institute, Ludwig-Maximilians-University Klinikum München, Munich, Germany